Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
A phase 1/2 trial of Auger Molecular Therapy (AMT) in advanced solid tumours, run by NanoRay Biotech Co., Ltd., now recruiting.
Overview
Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment is a phase 1/2 interventional study registered as NCT04807257 by NanoRay Biotech Co., Ltd., with 18 participants planned, started 2024-08-05 and due to reach its primary completion in 2025-12-31. Interventions recorded: Auger Molecular Therapy (AMT).
Setting
A First-in-Human Study of Auger Molecular Therapy (AMT) in Patients With Malignant Cutaneous Lesions From Advanced Solid Tumors
Phase
Phase 1/2
Sponsor
NanoRay Biotech Co., Ltd.
Registry
Enrolled
18 enrolled
Nothing links here yet.